Key takeaways
- 1:20,000–30,000 GCC Pompe disease incidence vs ~1:40,000 globally, elevated by consanguinity
- 25–35/yr Expected combined GCC infantile-onset (IOPD) detections annually via expanded newborn screening
- 55–65% Estimated baseline FVC (% predicted) at GCC late-onset Pompe disease diagnosis — indicating advanced disease at detection
Saudi Arabia's newborn screening expansion is expected to detect 25–35 infantile-onset Pompe cases a year, while late-onset patients are still diagnosed at just 55–65% predicted FVC after a limb-girdle-muscular-dystrophy diagnostic detour.
Pompe disease incidence in the GCC runs 1:20,000–30,000 live births versus roughly 1:40,000 globally, elevated by consanguinity; infantile-onset Pompe disease (IOPD) represents a larger proportion of GCC cases than in global series, consistent with the region's consanguinity pattern. Saudi Arabia added Pompe disease (GAA dried-blood-spot assay) to its national newborn screening programme in 2021, with an expected 25–35 combined GCC IOPD detections annually; the KFSH&RC metabolic genetics programme has treated approximately 120 Pompe patients of all subtypes over 15 years, making it the region's largest single-centre experience.
Late-onset Pompe disease (LOPD) follows a very different path: GCC patients typically present at age 20–40 with progressive proximal myopathy or respiratory decline, and diagnosis often comes only after multiple rheumatology or neurology assessments have first considered, and excluded, limb-girdle muscular dystrophy. Baseline forced vital capacity (FVC) at LOPD diagnosis in the GCC is estimated at 55–65% predicted, indicating advanced disease by the time GAA enzyme assay and genetic confirmation (both required before ERT initiation under NPHC criteria) finally occur. Enzyme replacement therapy itself requires metabolic specialist oversight and infusion capacity available at only 6–8 centres across all six GCC countries: KAMC and KFSH&RC in Saudi Arabia, AUH and SKMC in the UAE, Hamad Medical Corporation in Qatar, and Sultan Qaboos University Hospital in Oman. Patients outside these cities travel 100–300km for biweekly infusions, though KFSH&RC piloted a home infusion programme in 2022.
GCC Pompe disease burden — three defining dimensions
| Dimension | GCC Finding | Comparator | Implication |
|---|---|---|---|
| Incidence | 1:20,000–30,000 GCC incidence; IOPD proportionally more common | ~1:40,000 global incidence | Consanguinity sustains a structurally higher infantile-onset case rate |
| Diagnostic pathway (LOPD) | FVC 55–65% predicted at diagnosis; limb-girdle muscular dystrophy detour common | Earlier detection typical where GAA assay is first-line for unexplained proximal myopathy | Diagnostic education among rheumatology/neurology is the highest-leverage LOPD lever |
| Treatment infrastructure | 6–8 ERT infusion centres across six GCC countries | Patients outside these cities travel 100–300km biweekly | Home infusion expansion is the infrastructure lever most likely to improve GCC Pompe outcomes |
Sources: Al-Hassnan ZN, Clin Genet 2012; Saudi NBS Programme 2022; KFSH&RC Pompe LOPD case series 2015–2022; GCC metabolic disease network registry; KFSH&RC home infusion pilot data 2022.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How is Saudi Arabia's 2021 newborn screening expansion for Pompe disease changing the infantile-onset diagnosed population, and what does that mean for near-term ERT-eligible patient flow? • NBS-driven IOPD detection modelling • KFSH&RC 15-year treated-patient benchmark • ERT initiation timeline post-NBS identification
- Why do GCC late-onset Pompe disease patients pass through a limb-girdle muscular dystrophy diagnostic detour, and what does that mean for time-to-ERT and baseline lung function at diagnosis? • LOPD diagnostic pathway mapping (rheumatology/neurology detour) • baseline FVC benchmarking at diagnosis • GAA enzyme assay and genetic confirmation testing network
- Which GCC metabolic centres have ERT infusion capacity, and what does the geographic access gap mean for treatment continuity and the home infusion opportunity? • 6–8-centre infusion network mapping across six GCC countries • travel-distance burden analysis • home infusion pilot programme assessment (KFSH&RC 2022)
What's inside
-
1 · Pompe Disease Biology & the GAA Enzyme Deficiency 4 pp
- How acid alpha-glucosidase (GAA) deficiency causes glycogen accumulation across both infantile-onset and late-onset phenotypes
- Why disease severity spans from rapidly fatal infantile-onset to slowly progressive late-onset presentation
-
2 · GCC Epidemiology & the Consanguinity-Elevated Incidence 5 pp
- Why GCC Pompe incidence of 1:20,000-30,000 runs roughly 33-100% above the approximately 1:40,000 global rate
- How consanguinity elevates the proportion of infantile-onset cases relative to global case series
-
3 · Newborn Screening Expansion & Infantile-Onset Detection 4 pp
- Saudi Arabia's 2021 addition of the GAA dried-blood-spot assay to national newborn screening, expected to detect 25-35 combined GCC IOPD cases a year
- KFSH&RC's 15-year, roughly 120-patient treated cohort, the region's largest single-centre Pompe experience
-
4 · Late-Onset Pompe Disease — The Limb-Girdle Diagnostic Detour 5 pp
- Why GCC LOPD patients typically present at age 20-40 only after rheumatology or neurology first considers and excludes limb-girdle muscular dystrophy
- How baseline FVC of 55-65% predicted at diagnosis signals advanced disease by the time GAA assay and genetic confirmation occur
-
5 · Treatment Landscape — First-Gen vs Next-Gen Enzyme Replacement Therapy 4 pp
- Why GAA enzyme assay and genetic confirmation are both required under NPHC criteria before ERT initiation
- How next-generation enzyme replacement options compare against the first-generation alglucosidase alfa standard
-
6 · Metabolic Centre Network & the Infusion Access Gap 4 pp
- Mapping the 6-8 ERT infusion centres across all six GCC countries: KAMC and KFSH&RC in Saudi Arabia, AUH and SKMC in the UAE, Hamad Medical Corporation in Qatar, and Sultan Qaboos University Hospital in Oman
- Why patients outside these cities travel 100-300km for biweekly infusions, and what KFSH&RC's 2022 home infusion pilot signals for expansion
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Pompe Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the GCC Pompe patient population. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, GCC country focus, and epidemiological focus.
- 2. Scoping callAXLRx analyst confirms subpopulation scope, data sources, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment is built from the Saudi National Newborn Screening Programme, the KFSH&RC Pompe LOPD case series, and the GCC metabolic disease network registry, triangulated to separate NBS-driven IOPD detection from clinically diagnosed LOPD.
Formulary and access status is confirmed against NPHC and MOH listings and SFDA registration records rather than US/EU payer language, reflecting the GCC's metabolic-specialist-centred infusion care model.
- GCC Pompe incidence and consanguinity-effect figures verified against Al-Hassnan ZN, Clin Genet 2012
- Newborn screening expansion and expected annual IOPD detections verified against Saudi NBS Programme 2022
- LOPD diagnostic delay and baseline FVC figures verified against KFSH&RC Pompe LOPD case series 2015–2022
- Metabolic infusion centre network and home infusion pilot verified against GCC metabolic disease network registry and KFSH&RC home infusion pilot data 2022
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (patient flow model, drug comparison grid, or payer formulary data — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only — regulatory databases (SFDA, MOH, NPHC), peer-reviewed journals (Clinical Genetics), GCC national newborn screening programme data, and government formulary/coverage publications. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target GCC country, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions (additional GCC country deep-dives, pipeline agent profiles, or NPHC/MOH access modelling) can be added to any standard assessment. Commission via the intake form to start.